U.S. market Closed. Opens in 16 hours 41 minutes

BGLC | BioNexus Gene Lab Corp. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 0.5000 - 0.5880
52 Week Range 0.3100 - 9.49
Beta N/A
Implied Volatility N/A
IV Rank N/A
Day's Volume 216,263
Average Volume 164,773
Shares Outstanding 17,667,700
Market Cap 9,079,431
Sector Healthcare
Industry Medical - Diagnostics & Research
IPO Date 2021-01-08
Valuation
Profitability
Growth
Health
P/E Ratio -2.70
Forward P/E Ratio N/A
EPS -0.19
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 30
Country Malaysia
Website BGLC
BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
BGLC's peers: GLGI, IOSP, CBNT, FUL, PRM, AVOA, APGMF, ALTO, GEVO, GVDNY, OEC, NNOMF, SNES, LOOP, CRKN, GEVI, CMT, BCPC, NEU
*Chart delayed
Analyzing fundamentals for BGLC we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is passable. For more detailed analysis please see BGLC Fundamentals page.

Watching at BGLC technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on BGLC Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙